Diseases
Researchers at the Methodist Hospital Research Institute are conducting a Phase 2 clinical trial to study the efficacy of hypomethylating agents versus standard intensive chemotherapy induction in patients with acute myeloid leukemia (AML). The trial, led by principal investigator Shilpan Shah, MD, aims to enroll 112 adult patients and assess
Diseases
Motor neuron diseases (MNDs) are a group of progressive neurological disorders that damage motor neurons, leading to muscle weakness and loss of mobility. There is currently no cure for MNDs, and treatments can only relieve symptoms and enhance quality of life. Despite this, the disease is a significant concern, with
Diseases
Dementia associated with Alzheimer's disease is a general term that refers to a serious decline in cognitive function severe enough to interfere with daily life. The most common cause of dementia is Alzheimer's disease (AD), which accounts for about two-thirds of cases in individuals aged 65
Diseases
The Crohn's disease pipeline is booming with 180+ active players working on 200+ pipeline therapies, says DelveInsight's recent report. This translates to a robust treatment landscape with a plethora of drugs in various stages of development, from early-stage products to late-stage products. The report highlights key
Diseases
The first patient has been dosed in Upstream Bio's Phase 2 clinical trial, VENTURE, evaluating the efficacy and safety of verekitug in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD). This trial expands the global development program for verekitug into a third indication, following ongoing Phase 2 studies
Clinical trials
Researchers have presented data at the 2025 annual EULAR congress in Barcelona suggesting that early intensive therapy with biologics or combination conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) offers superior control of early moderate-to-severe psoriatic arthritis compared to standard step-up care. The SPEED trial, funded by the National Institute for Health
Diseases
Researchers from the University of Leeds conducted a landmark trial, known as the Flair trial, which aimed to assess whether a targeted cancer drug, ibrutinib, used alone or in combination with another drug, venetoclax, could outperform standard chemotherapy in treating chronic lymphocytic leukaemia (CLL). The trial, which took place at
Diseases
L2 Bio, the leader in adipose-derived stem cell banking, is actively recruiting Principal Investigators for its recently FDA-approved Phase 2B clinical trial for Crohn's Disease. This study aims to investigate a novel intravenous delivery of adipose-derived stem cells (ADSCs) for the treatment of Crohn's Disease. The
Diseases
Capstan Therapeutics, a clinical-stage biotechnology company, has successfully dosed the first participants in its Phase 1 trial of CPTX2309, a targeted lipid nanoparticle that delivers an anti-CD19 CAR mRNA preferentially to CD8-expressing cytotoxic T cells. The trial aims to evaluate the safety, tolerability, and pharmacodynamic activity of CPTX2309 in healthy
Diseases
Capsida Biotherapeutics, a clinical-stage genetic medicines company, has announced the clearance of the Investigational New Drug (IND) application for CAP-003, a potential best-in-class intravenously administered gene therapy, to enter clinical trials for Parkinson's disease associated with GBA mutations (PD-GBA). This milestone marks the second wholly owned clinical program
Diseases
Alzheimer's disease researchers at the University of Texas Health Science Center San Antonio have conducted a pilot phase 1 clinical trial to investigate the effects of rapamycin on humans. Although rapamycin has shown potential in extending lifespan and treating pathologies in animal models, its clinical application remains underexplored.
Clinical trials
A new systematic review, published in the Journal of PeriAnesthesia Nursing, has found that ketamine may be effective in reducing postoperative depressive symptoms in high-risk adult patients undergoing surgery. The review, conducted by investigators at the University of Pennsylvania, examined existing literature on the use of ketamine as a prophylactic
